Which sapropterin trials have publicly described “patient examples”?
I can, but I need one more detail: sapropterin is studied in multiple trials (different age groups, causes of hyperphenylalaninemia, and trial designs). The “patient examples” you may be looking for could be any of the following:
- Individual case-style responses (e.g., responders vs non-responders)
- Trial inclusion criteria examples (who was enrolled)
- Concrete baseline and outcome values reported for particular participants (phenylalanine levels, dose, weeks to response)
- Real-world case reports published alongside trial results
If you tell me the trial name or study ID, I can pull specific patient examples
Please share at least one of these so I can provide accurate, specific patient-level examples from the right report:
- The study identifier (e.g., NCT number)
- The publication title or author/year
- The indication (classic PKU vs mild HPA vs BH4-responsive status)
- Age group (pediatric vs adult)
- Whether you mean clinical trial registry summaries or peer-reviewed papers
Common “sapropterin patient examples” people usually mean (so you can confirm)
For sapropterin, trial reporting often distinguishes patients by BH4 responsiveness and shows examples through things like:
- Baseline phenylalanine (Phe) range and how much it drops after sapropterin
- Time to achieve a target Phe reduction (often within weeks)
- Dose used and whether the patient is classified as a “responder”
- Cases where Phe does not meaningfully improve (non-response), even if sapropterin is tolerated
Quick check: do you mean PKU/BH4 responsiveness trial participants?
If you confirm you mean “patients who responded vs did not respond,” I can summarize specific participant examples (with reported numbers) from the trial you choose—once I know which trial.
One option: point me to the exact source you’re using
If you paste a link (Drug labels, trial registry page, or the paper), I can extract the specific patient examples exactly as written there.
Sources: none provided yet.